Literature DB >> 7754762

Standard and intermediate risk acute lymphoblastic leukemia in Poland: a report of the Polish Children's Leukemia/Lymphoma Study Group.

U Radwanska1, D Michalewska, P Kolecki, J Armata, W Balwierz, J Boguslawska-Jaworska, A Chybicka, R Cyklis, J Kowalczyk, M Ochocka.   

Abstract

A total of 527 children with acute lymphoblastic leukaemia (ALL) from the most frequent risk groups: standard risk group (SRG) and intermediate risk group (IRG) were treated between 1987 and 1991 according to an intensified treatment program (based on the BFM protocol) including the use of an intermediate dose of methotrexate in the IRG. A comparison of the treatment results in this group from 513 children treated between 1981 and 1987 indicates that the chance for a 6 year event-free survival has increased to 73% (previously 55%).

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7754762     DOI： 10.1111/j.1442-200x.1995.tb03681.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN： 0374-5600


  3 in total

1.  Homozygosity for the rs9939609T allele of the FTO gene may have protective effect on becoming overweight in survivors of childhood acute lymphoblastic leukaemia.

Authors:  Skoczen Szymon; Miroslaw Bik-Multanowski; Walentyna Balwierz; Jacek J Pietrzyk; Marcin Surmiak; Wojciech Strojny; Danuta Galicka-Latala; Jolanta Gozdzik
Journal:  J Genet       Date:  2011-08       Impact factor: 1.166

2.  Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene -18G > A and leptin receptor genes K109R and Q223R, in survivors of childhood acute lymphoblastic leukemia.

Authors:  Szymon Skoczen; Przemyslaw J Tomasik; Miroslaw Bik-Multanowski; Marcin Surmiak; Walentyna Balwierz; Jacek J Pietrzyk; Krystyna Sztefko; Jolanta Gozdzik; Danuta Galicka-Latała; Wojciech Strojny
Journal:  J Exp Clin Cancer Res       Date:  2011-06-01

3.  Late effects in survivors of childhood acute lymphoblastic leukemia in the context of selected gene polymorphisms.

Authors:  Kinga Kwiecinska; Wojciech Strojny; Danuta Pietrys; Miroslaw Bik-Multanowski; Maciej Siedlar; Walentyna Balwierz; Szymon Skoczen
Journal:  Ital J Pediatr       Date:  2018-08-15       Impact factor: 2.638
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.